BMN 111 administration via vial and syringe
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Mar 15, 2023 → Jun 14, 2023
NCT ID
NCT05813314About BMN 111 administration via vial and syringe
BMN 111 administration via vial and syringe is a phase 1 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05813314. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05813314 | Phase 1 | Terminated |
Competing Products
20 competing products in Achondroplasia